Saturday 17 October 2026
Export TECX’s income statement to Excel — free account
Tectonic Therapeutic, Inc.
TECX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 10.3%, free cash flow fell 46.7% and total debt fell 94.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
20.65
0.65
−3.05%
Follow TECX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (33.80%) | (31.42%) | (37.82%) | (32.21%) |
+8 more TTM periods Free account |
|
| (32.23%) | (29.74%) | (35.83%) | (30.20%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(38.71%) | (36.62%) | (29.79%) | (25.37%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(3.82) | (3.49) | (3.29) | (3.34) | |
Free Cash Flow |
(72.38) | (65.54) | (60.22) | (62.58) | |
Capital Expenditures |
(0.24) | (0.13) | (0.14) | (0.14) | |
| Other line items | |||||
Cash ROIC |
(16.05%) | (14.02%) | (11.91%) | (11.66%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(2,373.12) | (1,824.29) | (1,333.90) | (1,033.91) | |
Operating CF/Net income |
0.84 | 0.78 | 0.81 | 0.93 | |
Depreciation/Fixed assets |
1.47 | 1.29 | 1.16 | 1.10 | |
Capex/Depreciation |
(0.19) | (0.10) | (0.10) | (0.09) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.80) | (3.48) | (3.28) | (3.34) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates